KIMS

Krishna Institute of Medical Sciences Cash Flow

₹694.40+0.14%
Market cap
₹27,786 crore
P/E
136.0
P/B
12.36
ROE
11.0%
Dividend yield
1.20%

In the year ended Mar 2022, Krishna Institute of Medical Sciences generated ₹1,400 crore from operating activities, invested ₹600 crore and paid out ₹550 crore on financing activities. Net cash flow for the year was ₹250 crore. Free cash flow was ₹950 crore.

Krishna Institute of Medical Sciences cash flow statement

Financial years, newest first. Negative figures are cash outflows.

Krishna Institute of Medical Sciences cash flows (₹ crore)
ItemMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activities1,400432521582511
Cash from investing activities-600-547-753-1,116-1,452
Cash from financing activities-55020217543940
Net cash flow250-95-159-1
Capital expenditure—————
Free cash flow950-142-126-427-917

Source: Company filings, in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Krishna Institute of Medical Sciences cash flow — frequently asked questions

What is Krishna Institute of Medical Sciences' operating cash flow?

Krishna Institute of Medical Sciences' cash flow from operating activities was ₹1,400 crore in the year ended Mar 2022, rose 224.07% from ₹432 crore in Mar 2023.

What is Krishna Institute of Medical Sciences' free cash flow?

Krishna Institute of Medical Sciences' free cash flow — operating cash flow minus capital expenditure — was ₹950 crore in Mar 2022.

How much did Krishna Institute of Medical Sciences spend on investing activities?

Net cash used in investing activities was ₹600 crore in Mar 2022. This covers capital expenditure, acquisitions and the purchase or sale of investments.

Same Data For Peers

Trade Krishna Institute of Medical Sciences With ATS

Track KIMS live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.